Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BeiGene, Ltd.

< Previous 1 2 3 Next >
BeiGene Reports First Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Introduces Global Environmental, Social, and Governance Strategy
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Reports Third Quarter 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Inclusion in FTSE Russell Indices
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research on August 25, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Reports Second Quarter 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.